Check Cap
Check Cap
CHEK
NASDAQ
1.89
USD
145.45%
About
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide.
The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 5.3K |
| Three Month Average Volume | 237.9K |
| High Low | |
| Fifty-Two Week High | 4.625 USD |
| Fifty-Two Week Low | 1.78 USD |
| Fifty-Two Week High Date | 21 Sep 2023 |
| Fifty-Two Week Low Date | 07 Mar 2024 |
| Price and Volume | |
| Current Price | 1.885 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -9.89% |
| Thirteen Week Relative Price Change | -23.26% |
| Twenty-Six Week Relative Price Change | -16.78% |
| Fifty-Two Week Relative Price Change | -48.31% |
| Year-to-Date Relative Price Change | -23.47% |
| Price Change | |
| One Day Price Change | -2.33% |
| Thirteen Week Price Change | -17.86% |
| Twenty-Six Week Price Change | -8.50% |
| Five Day Price Change | -0.26% |
| Fifty-Two Week Price Change | -35.22% |
| Year-to-Date Price Change | -9.38% |
| Month-to-Date Price Change | -6.22% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.04867 USD |
| Book Value Per Share (Most Recent Quarter) | 4.04867 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.04867 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.04867 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.01797 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.00373 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.00415 USD |
| Normalized (Last Fiscal Year) | -2.75991 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.00373 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.00415 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.00373 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.00415 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.23139 USD |
| Cash Per Share (Most Recent Quarter) | 4.23139 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.96748 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.96786 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.91331 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -39.24% |
| Tangible Book Value (5 Year) | 12.70% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -2.46% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 0.52% |
| EPS Change (Trailing Twelve Months) | 94.66% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -24,756,000 |
| Net Debt (Last Fiscal Year) | -24,756,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 19 |
| Current Ratio (Most Recent Quarter) | 19 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -17,037,000 |
| Free Cash Flow (Trailing Twelve Months) | -17,037,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -49.87% |
| Return on Assets (Trailing Twelve Months) | -49.87% |
| Return on Assets (5 Year) | -54.23% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -54.06% |
| Return on Equity (Trailing Twelve Months) | -54.06% |
| Return on Equity (5 Year) | -61.34% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -53.46% |
| Return on Investment (Trailing Twelve Months) | -53.46% |
| Return on Investment (5 Year) | -60.24% |